Assenagon Asset Management S.A. Has $195 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Assenagon Asset Management has reduced its stake in Edwards Lifesciences by 39.3%, selling 1,614,423 shares, leaving it with approximately 2.5 million shares valued at nearly $195 million.
• Edwards Lifesciences reported better-than-expected Q2 earnings, with a net income of $0.67 EPS, surpassing the forecast of $0.62, and a revenue of $1.53 billion compared to expectations of $1.49 billion.
• Despite a slight stock decline of 0.2% recently, analysts have raised their price targets for Edwards Lifesciences, with a consensus average price target of approximately $87.17.

Assenagon Asset Management S.A. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 39.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,493,234 shares of the medical research company's stock after selling 1,614,423 shares during the period. Assenagon Asset Management S.A. owned approximately 0.43% of Edwards Lifesciences worth $194,996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. IFM Investors Pty Ltd lifted its position in shares of Edwards Lifesciences by 2.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 124,259 shares of the medical research company's stock worth $9,718,000 after purchasing an additional 2,930 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $108,000. NorthCrest Asset Manangement LLC acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $330,000. Wealth Enhancement Advisory Services LLC lifted its position in shares of Edwards Lifesciences by 111.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company's stock worth $12,532,000 after purchasing an additional 86,186 shares during the last quarter. Finally, Wedmont Private Capital lifted its position in shares of Edwards Lifesciences by 22.6% during the 2nd quarter. Wedmont Private Capital now owns 12,090 shares of the medical research company's stock worth $933,000 after purchasing an additional 2,230 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Morgan Stanley boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Barclays boosted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Finally, Wall Street Zen cut Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 13th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average target price of $87.17.

Edwards Lifesciences Price Performance

NYSE EW traded down $0.16 during trading hours on Friday, reaching $74.39. 8,177,895 shares of the company's stock were exchanged, compared to its average volume of 3,799,900. The stock has a market cap of $43.67 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 3.59 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $78.69 and a 200-day moving average of $75.53. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.